ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0952

Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21

Tingting Mills1, Minghua Wu2, Hydia Puente3, Jerry Alonso4, Julio charles4, Maureen Mayes4 and Shervin Assassi5, 1Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, 2Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 3UTHealth-Houston, Houston, TX, 4Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 5University of Texas McGovern Medical School at Houston, Houston, TX

Meeting: ACR Convergence 2023

Keywords: Collagen, Fibroblasts, Dermal, Growth Factor, Micro-RNA, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Nudix Hydrolase 21 (NUDT21, also known as CFIm25) is a master regulator of alternative polyadenylation. Previous studies have revealed that NUDT21 is significantly decreased in systemic sclerosis (SSc) skin and that its downregulation in fibroblasts potentiates both skin and lung fibrosis (Weng T et al. J Clin Invest. 2019 & J Exp Med 2020). This study aims to investigate the upstream mechanisms that lead to NUDT21 repression in skin fibrosis.

Methods: NUDT21 levels in cells treated with different cytokines were determined by western blot and RT-qPCR. Dual-luciferase assays were performed to determine the micro RNA (miRNA) regulation of NUDT21. MiR-181a and -181b mimics and inhibitors were injected subcutaneously 10 days after the initial subcutaneous bleomycin treatment to determine their effects on skin fibrosis (n≥ 5 per group).

Results: In comparison to IL4, IL6, IL13, and PDGF, transforming growth factor β (TGFβ1) led to a stronger downregulation of NUDT21 in healthy control (HC) dermal fibroblasts (Fig. 1A). Further investigation showed that TGFβ did not downregulate NUDT21 transcript until 48 hours after treatment, suggesting that it regulated NUDT21 through an indirect mechanism such as miRNA induction. Screening potential NUDT21 targeting miRNAs revealed that miR-181a and -181b were elevated in TGFβ1 treated human dermal fibroblasts and bleomycin-induced skin fibrosis in mice (Fig. 1B-C). Consistent with these findings, miR-181a and -181b were both significantly increased in primary dermal fibroblasts from 27 patients with early diffuse SSc compared to fibroblasts obtained from 20 matched HCs while the levels of other NUDT21 targeting miRNAs were not increased (Fig. 1D). Both miR-181a and -181b could directly bind NUDT21 3’UTR to repress NUDT21 expression in skin fibroblasts (Fig. 1E-F). Functional studies demonstrated that miR-181a and -181b inhibitors attenuated bleomycin-induced skin fibrosis murine models in association with decreased NUDT21 expression (Fig.2), while miR-181a and -181b mimics exaggerated bleomycin-induced skin fibrosis.

Conclusion: Taken together, these findings suggest miR-181a/b play a role in SSc pathogenesis and are potential therapeutic options for skin fibrosis.

Supporting image 1

Supporting image 2


Disclosures: T. Mills: None; M. Wu: Boehringer-Ingelheim, 5, Janssen, 5, Prometheus Biosciences, 5; H. Puente: None; J. Alonso: None; J. charles: None; M. Mayes: Boehringer Ingelheim, 1, 5, British Medical Journal, 9, Corbus, 5, EICOS, 1, 5, Horizon Pharma, 5, Medtelligence, 6, Mitsubishi Tanabe, 1, 5, Oxford University Press, 9, Prometheus, 5, Springer International Publishing, 9; S. Assassi: AstraZeneca, 2, aTyr, 2, Boehringer Ingelheim, 2, 5, CSL Behring, 2, Janssen, 5, Merck, 2, Momenta, 5, TeneoFour, 2.

To cite this abstract in AMA style:

Mills T, Wu M, Puente H, Alonso J, charles J, Mayes M, Assassi S. Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/unraveling-the-role-of-mir-181-in-skin-fibrosis-pathogenesis-by-targeting-nudt21/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unraveling-the-role-of-mir-181-in-skin-fibrosis-pathogenesis-by-targeting-nudt21/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology